Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients  by Falagas, M.E. & Vardakas, K.Z.
EDITORIAL 10.1111/j.1469-0691.2006.01405.x
Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients
M. E. Falagas1,2 and K. Z. Vardakas1
1Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece and 2Department of Medicine, Tufts
University School of Medicine, Boston, Massachusetts, USA
ABSTRACT
Ganciclovir and its prodrug, valganciclovir, are more effective than acyclovir in preventing cytomeg-
alovirus (CMV) infection and disease in solid-organ transplant recipients. However, the indirect effects
of prophylactic use of ganciclovir and acyclovir are comparable, and the greater effectiveness of
ganciclovir may be compensated for by less drug-related toxicity with acyclovir or valacyclovir. No
conclusive data exist concerning the best technique and duration of surveillance for CMV infection in
patients for whom active surveillance for late-onset CMV should be performed, i.e., those reaching the
end of prophylaxis. Only large randomised controlled trials, with long follow-up periods, will provide
deﬁnitive conclusions regarding the comparative prophylactic roles of the major antiviral agents in this
population, and how their use ﬁts with a strategy of active surveillance and pre-emptive therapy.
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Cytomegalovirus (CMV) disease is the most
common infection post-transplantation, and is
estimated to affect > 50% of transplant recipients
within the ﬁrst year after transplantation and has
a negative effect on their survival [1]. CMV
replication has been associated with increased
episodes of rejection and periods of hospitalisa-
tion [2]. Therefore, various prophylactic regimens
against this viral infection have been investigated
for use in solid-organ transplant recipients.
A drug considered for prophylactic use should
meet speciﬁc criteria, including high effective-
ness, low toxicity and low cost; in addition, it
should be administered in a formulation that is
easy to take and ensures good compliance. How-
ever, none of the currently available antiviral
drugs meets all of these criteria. Table 1 summa-
rises the advantages and disadvantages of the
available drugs for antiviral prophylaxis when
used in solid-organ transplant recipients [2–5].
Valganciclovir and ganciclovir are highly effective
and are the agents used most frequently for
prophylaxis in solid-organ transplant recipients
[3]. Valacyclovir, the ester of acyclovir, was
reported to be more effective than acyclovir in
heart transplant recipients [6]. In addition, in a
small randomised controlled trial, the effective-
ness of valacyclovir was similar to that of oral
ganciclovir in low-risk patients [7].
The data from the available clinical trials and
meta-analyses suggest that all of the aforemen-
tioned drugs can be considered for prophylactic
use in solid-organ transplant recipients [8–10]. As
expected, when acyclovir was compared directly
with ganciclovir, the latter was more effective in
reducing both CMV disease and infection post-
transplantation (p < 0.001) [2–5]. However, sev-
eral issues must be considered regarding the
overall effectiveness and toxicity of the various
prophylactic antiviral agents when used in this
population.
First, it is worth noting that the indirect effects
of prophylaxis (mortality, graft rejection, graft
loss) with either ganciclovir or acyclovir are
comparable [11]. However, use of valacyclovir
resulted in fewer acute rejection episodes than did
use of ganciclovir in a study of renal transplant
recipients [7].
Second, prophylaxis with ganciclovir or valg-
anciclovir results in a delay in the onset of CMV
disease after transplantation. In ganciclovir trials,
this delay was associated with more severe
invasive CMV disease and increased mortality,
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possibly because the disease was diagnosed in an
advanced stage during the late post-transplanta-
tion period [12]. On the other hand, the time to
onset of CMV disease in acyclovir trials was quite
short following transplantation (most of the rand-
omised controlled trials report a mean or a
median time of 50 days) [13,14], meaning that
the diagnosis is veriﬁed at a time when monitor-
ing for CMV disease is maximal, and that the
morbidity related to CMV disease does not
necessarily translate to increased mortality. Vala-
cyclovir prophylaxis also seems to be associated
with a delay in the onset of CMV disease [15].
Unfortunately, the available data from random-
ised controlled trials are not sufﬁcient to conclude
which drug is superior in reducing the incidence
of late-onset CMV disease. In addition, no formal
guidelines have been developed regarding the
technique and the duration of surveillance for
patients reaching the end of prophylaxis, which is
the group for which active surveillance for late-
onset CMV should be performed [16]. It is
probably reasonable to consider active surveil-
lance for a period of 6–12 months for solid-organ
transplant recipients with a higher risk for CMV
disease who received antiviral prophylaxis, i.e.,
CMV-seronegative recipients of organs from
CMV-seropositive donors. However, there are
no conclusive data concerning the comparative
prognostic utility of various serological and
molecular techniques for the development of
late-onset CMV in this population.
Third, ganciclovir and valganciclovir are asso-
ciated with more episodes of leukopenia (leading
to discontinuation of prophylaxis in some pa-
tients) than acyclovir [11]. Prolonged leukopenia
may play a role in the inhibition of the reactiva-
tion of the speciﬁc anti-CMV lymphocytes in
CMV-seropositive recipients, and thus these
patients are more susceptible to CMV disease
when the prophylactic effect of ganciclovir is
withdrawn.
Fourth, data suggest that a signiﬁcant propor-
tion of transplant recipients who develop CMV
disease after prophylaxis with ganciclovir will be
infected with a resistant virus. This proportion
may rise to 20% of infected patients [17]. To date,
there is no evidence for the development of
resistant viruses following prophylactic adminis-
tration of valganciclovir in solid-organ transplant
recipients. However, there are reports of devel-
opment of resistance to ganciclovir after the
treatment with valganciclovir of CMV retinitis in
patients infected with human immunodeﬁciency
virus [18]. Although the armamentarium against
CMV also includes foscarnet and cidofovir (and
other antiviral agents under development or
investigation), these agents are used only when
ganciclovir resistance is suspected [19]. The data
concerning resistance to antiviral agents suggest
that ganciclovir should be reserved whenever
other drugs are similarly effective.
It is currently a matter of debate whether
universal prophylaxis or active surveillance and
pre-emptive therapy is the most suitable manage-
ment strategy for transplant recipients at risk for
development of CMV infection. In a preliminary
report of a meta-analysis, it was reported that
both strategies are highly effective in reducing the
risk for development of CMV disease (42nd
Annual Meeting of the Infectious Diseases Society
of America, abstract 639), and that both have
advantages and disadvantages. Speciﬁcally, pro-
phylaxis is effective in reducing all indirect effects
of CMV disease in all transplant recipients. In
addition, trials comparing these two methods
Table 1. Advantages and disadvan-
tages of prophylactic antiviral drugs
used in solid-organ transplant recip-
ients
Drug
Prophylaxis
criteriaa
Resistance to
ganciclovir Indirect effects Leukopenia
Acyclovir C, S None Mortality, graft loss, acute graft
rejection, and superinfection
are comparable to those with
ganciclovir and better than
those with placebo ⁄no treatment
Similar to placebo
Valacyclovir E, S None As with acyclovir, but the data
for the direct comparison with
ganciclovir are limited
Similar to acyclovir
Ganciclovir E, S Up to 20% Similar to acyclovir More than acyclovirb
Valganciclovir E, A, S Not yet
reported in
transplant
recipients
Similar to ganciclovir More than ganciclovirc
aC, low cost; S, safety; E, effectiveness; A, ease of administration.
bStatistically signiﬁcant.
cNot statistically signiﬁcant.
604 Clinical Microbiology and Infection, Volume 12 Number 7, July 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 603–605
directly in recipients at high risk for development
of CMV disease indicated that prophylaxis was
more cost-effective than pre-emptive therapy [16].
However, pre-emptive therapy is associated with
fewer episodes of late-onset CMV disease, lower
drug-related costs, and probably involves a lower
risk for development of viruses resistant to
ganciclovir [12,16].
The apparent superiority of ganciclovir and
valganciclovir over acyclovir as antiviral prophy-
laxis in this population should not be taken for
granted. The greater effectiveness of ganciclovir,
compared with acyclovir, in preventing CMV
disease may be offset by a reduced risk for
development of resistant viruses and less drug-
related toxicity with the use of acyclovir. In
addition, it should be emphasised that no survival
beneﬁt has ever been shown in favour of ganci-
clovir in solid-organ transplant recipients. Only
large randomised controlled trials with a long
follow-up period will provide deﬁnitive conclu-
sions concerning the comparative prophylactic
roles of the major antiviral agents in solid-organ
transplant recipients. Until the results of such
trials are available, acyclovir and valacyclovir
should not be excluded from the options for
prophylaxis in solid-organ transplant recipients.
Formulations of acyclovir, or other effective
antiviral drugs with molecules similar to acyclo-
vir, which may be given orally, preferably once-
daily, should become one of the goals of both
the drug development research community and
industry.
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